Oscar Health Surges 4.37% on $400M Volume 294th-Ranked Stock Sparks Profitability Debate Amid 52-Week Rally

. 8, , ranking it 294th among U.S. equities. , signaling improved market leadership potential over the past 52 weeks.

, the company faces profitability challenges, . Analysts remain cautious, assigning five sell ratings, three holds, and no buys, . , suggesting a short-term upward trend.

Oscar’s strategic focus on healthcare technology, including platforms like +Oscar and Campaign Builder, aims to enhance operational efficiency and provider engagement. Its reinsurance offerings also provide a diversified revenue stream in a regulated industry. However, .

To run this back-test robustly I need a few extra details and (because of current tool limitations) possibly to narrow the scope a bit. Could you please confirm the points below? 1. Universe • US common stocks only (listed on NYSE / NASDAQ / AMEX) – is that correct? • If another market or a custom list is intended, please specify. 2. , ? (Either is fine, . Rebalancing & position size • Rebalanced every trading day, ? • Any transaction-cost assumption? . Tool capability note The current back-test engine exposed to Aime handles one ticker at a time. . Two practical options: A) Narrow the test to one ETF or index proxy (e.g., . B) I run an external Python back-test (I can do this), . Which option would you prefer? (If you need the full cross-sectional test, I’ll proceed with option B.) Once I have these clarifications I can launch the data retrieval and begin the back-test.